文献速递胃肠动力与功能性疾病

无麸质饮食可减轻肠易激综合征伴抗麦胶蛋白IgG患者的症状尤其是腹泻

Gluten-Free Diet Reduces Symptoms, Particularly Diarrhea, in Patients With Irritable Bowel Syndrome and Antigliadin IgG.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-08-19

在加拿大汉密尔顿一家大学医院开展的前瞻性研究纳入50例肠易激综合征患者(罗马III标准,各亚型)和25名健康对照,于2012至2016年间比较无麸质饮食前后症状与胃肠传输。无麸质饮食后,抗麦胶蛋白IgG和IgA阳性者较阴性者报告更少腹泻(P = .03),症状改善比例分别为75%(18/24)和38%(8/21)。

要点

  • 无麸质饮食后抗麦胶蛋白IgG和IgA阳性者较阴性者腹泻更少(P = .03)。
  • 抗麦胶蛋白IgG和IgA阳性者18/24例(75%)症状改善,阴性者8/21例(38%)改善。
  • 抗麦胶蛋白IgG与症状整体减少相关(校正比值比128.9;95%CI 1.16-1427.8;P = .04)。

核心结论

  • 抗麦胶蛋白IgG可作为生物标志物识别无麸质饮食后症状(尤其是腹泻)可能减轻的肠易激综合征患者。
  • 需要更大规模研究验证这些发现。

研究设计与样本

  • 前瞻性研究,纳入50例肠易激综合征患者(罗马III标准,各亚型,伴或不伴麸质血清学反应,即抗麦胶蛋白IgG和IgA)和25名健康对照。
  • 研究于2012至2016年在加拿大安大略省汉密尔顿一家大学医院进行。
  • 研究无麸质饮食4周前后的胃肠传输、肠道症状、焦虑、抑郁、躯体化、饮食习惯和微生物群组成,并测定HLA-DQ2/DQ8状态。
  • 无麸质饮食依从性由营养师评估并通过检测粪便中麸质肽段判断。

主要发现

  • 基线时患者间症状无差异,但无麸质饮食后抗麦胶蛋白IgG和IgA阳性者较阴性者报告更少腹泻(P = .03)。
  • 与基线相比,抗麦胶蛋白IgG和IgA阳性者24例中18例(75%)肠易激综合征症状改善,阴性者21例中8例(38%)改善。
  • 抗麦胶蛋白IgG和IgA阳性者便秘、腹泻和腹痛均减轻,而阴性者仅腹痛减轻。
  • 抗麦胶蛋白IgG和IgA阳性者中胃肠传输正常化的比例更高。
  • 两组焦虑、抑郁、躯体化和幸福感均增加。

局限性

  • 需要更大规模研究验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Many patients with irritable bowel syndrome (IBS) perceive that their symptoms are triggered by wheat-containing foods. We assessed symptoms and gastrointestinal transit before and after a gluten-free diet (GFD) in unselected patients with IBS and investigated biomarkers associated with symptoms. METHODS: We performed a prospective study of 50 patients with IBS (ROME III, all subtypes), with and without serologic reactivity to gluten (antigliadin IgG and IgA), and 25 healthy subjects (controls) at a university hospital in Hamilton, Ontario, Canada, between 2012 and 2016. Gastrointestinal transit, gut symptoms, anxiety, depression, somatization, dietary habits, and microbiota composition were studied before and after 4 weeks of a GFD. HLA-DQ2/DQ8 status was determined. GFD compliance was assessed by a dietitian and by measuring gluten peptides in stool. RESULTS: There was no difference in symptoms among patients at baseline, but after the GFD, patients with antigliadin IgG and IgA reported less diarrhea than patients without these antibodies (P = .03). Compared with baseline, IBS symptoms improved in 18 of 24 patients (75%) with antigliadin IgG and IgA and in 8 of 21 patients (38%) without the antibodies. Although constipation, diarrhea, and abdominal pain were reduced in patients with antigliadin IgG and IgA, only pain decreased in patients without these antibodies. Gastrointestinal transit normalized in a higher proportion of patients with antigliadin IgG and IgA. Anxiety, depression, somatization, and well-being increased in both groups. The presence of antigliadin IgG was associated with overall reductions in symptoms (adjusted odds ratio compared with patients without this antibody, 128.9; 95% CI, 1.16-1427.8; P = .04). Symptoms were reduced even in patients with antigliadin IgG and IgA who reduced gluten intake but were not strictly compliant with the GFD. In controls, a GFD had no effect on gastrointestinal symptoms or gut function. CONCLUSIONS: Antigliadin IgG can be used as a biomarker to identify patients with IBS who might have reductions in symptoms, particularly diarrhea, on a GFD. Larger studies are needed to validate these findings. ClinicalTrials.gov: NCT03492333.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Pinto-Sanchez MI, Nardelli A, Borojevic R, et al. Gluten-Free Diet Reduces Symptoms, Particularly Diarrhea, in Patients With Irritable Bowel Syndrome and Antigliadin IgG. Clin Gastroenterol Hepatol. 2020. PMID: 32827724. doi:10.1016/j.cgh.2020.08.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。